 expand our current processes to assure they are applicable to AAV serotypes 1, 2 and 5. We will also address the significant problem of AAV aggregation. Finally, we will conduct an in vivo mouse study to determine the correlation between purity, biological activity and safety through the evaluation of immune and histopathological responses to the vector
expand our current processes to assure they are applicable to AAV serotypes 1, 2 and 5. We will also cover the meaning trouble of AAV aggregation. Finally, we will conduct an in vivo shiner study to determine the correlation between honor, biological activeness and safety through the evaluation of immune and histopathological response to the vector
 exoand our current processts to assure they are ap'licabls to AAV serotypes 1, 2 and 5. We will aldo addrtfs the significant problem lf AAV atgrejation. Finally, wx will conduct wn iu tivo mouse studi to determite the correladiun between purity, biological activity and sagehy through the evaktatikn of immune and histopathological responves to the vevtor
expand our current processes to assure they to serotypes 1, and 5. We problem AAV aggregation. Finally, will conduct an vivo mouse study to determine the between purity, biological activity and safety through the evaluation of immune and histopathological to the vector
 expand our current processes To assure thEy are AppLicAbLe to aAV sErotypes 1, 2 and 5. We wILl alSo address the significanT probLeM Of AAv AgGregaTion. FinALlY, WE wiLl CoNduCt AN iN vivo MouSe study To determinE thE cOrrelation beTWeEn purity, biOloGical activitY anD safetY tHroUGh the EvaLuatiOn of imMUne and HistopathOlOGical rESponses TO ThE vecTor
 expand our current proces ses to ass ure t hey  ar eappl icab le to AAV sero t ypes  1, 2 and 5. We will a lso a dd r esst he  sign ificant pr o b lem  o fAAV  a g gr egati on.  Finall y, we will  co nd uct an in vi v omouse stud y t o determinethe  corre la tio n  betw een  puri ty, bi o logica l activit ya nd saf e ty thro u g htheevaluation of imm u ne and histopatho logica lr es p o nse s t o the vect or 
 expand_our current_processes to assure they_are applicable_to_AAV serotypes_1,_2 and 5._We will also_address the significant problem_of AAV aggregation._Finally,_we will conduct an in vivo mouse study to determine the correlation between purity,_biological_activity and_safety_through_the evaluation of immune and_histopathological responses to the vector